Predictors of survival in patients with glioblastomas of the cerebral hemispheres
Objective: to determine the main prognostic factors of the survival of patients with glioblastomas (GLB) of the cerebral hemispheres.
Materials and methods. A prospective study of treatment outcomes of patients with GLB examined and treated in Mechnikov Dnipropetrovsk Regional Clinical Hospital from 2009 to 2014 inclusive. The studies were consecutively included 77 patients with GLB operated by the first treater. There were distinguished 4 types of neoplasm removal by the removed tumor volume: gross-total resection (GTR); near-total resection (NTR); sub-total resection (STR); partial resection (PR).
Results. There were 47 women and 30 men of the 77 patients with GLB aged from 21 to 72 years; average age was 51.9 ± 12.6 years. The cases were distributed by the tumor volume removed as follows: GTR – 20, NTR – 32, STR – 13, PR – 12 cases. Thus, advanced radical surgery (GTR + NTR) was performed in 52 (67.5%) cases.
Median survival in the total group of patients (n=77) was 353.5 days (11.6 months). The best results were achieved mostly in the young patients. The median survival of patients with GLB aged 21-40 years was 21.3 months. The use of adjuvant therapy leads to significant increase in life expectancy of patients. The median survival rate for GLB removal followed by radiotherapy was 16.1 months, and for combined treatment — 18.2 months. When removing GLB, which does not spread to functionally important and deep parts of the brain, one should try to perform GTR, which ensures long-term survival. The median survival of patients after GTR was 22.3 months.
Conclusions. The main statistically significant prognostic factors of survival of patients revealed were patients’ age (p=0.004), the tumor volume removed (p=0.00001), the presence and character of adjuvant therapy (p=0.00002).
Full Text:PDF (Українська)
1. Chomolyak Yu, Smolanka V, Studenyak T [Outlook for the treatment and prognosis of high-grade brain gliomas]. Ukrainian Neurosurgical Journal. 2013;(3):4-9. Ukrainian. [Abstract/Full Text]
2. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016 Jun;131(6):803-20. [CrossRef] [PubMed]
3. Smolin AV, Bekyashev AH, Kobyakov GL, Sharabura TM, Mufazalov FF, Kanischeva NV, Bumagina VO. [First results of the Russian multicenter epidemiology project on the malignant gliomas]. Journal of modern oncology. 2014;16(2):50-55. Russian. [eLIBRARY.RU]
4. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005 Mar 10;352(10):987-96. [CrossRef] [PubMed]
5. Fedorenko ZP, Michailovich YuYu, Goulak LO, Gorokh YeL, Ryzhov AYu, Soumkina OV, Koutsenko LB. Cancer in Ukraine, 2014-2015. Incidence, mortality, activities of oncological service. Kolesnik OO, editor. [Internet]. Bulletin of National Cancer Registry of Ukraine. 2016;17. [cited 2017 April 12]. Available from: http://www.ncru.inf.ua/publications/BULL_17/index_e.htm
6. Rozumenko VD, Yavorski AA [Dynamics of the Survival of Elderly Patients with Glial Tumors of the Brain Hemispheres]. Ukrayinskyy zhurnal maloinvazyvnoyi ta endoskopichnoyi khirurhiyi. 2014;18(4):13-15. Ukrainian. [VernadskyNLU]
7. Glavatsky O, Butrym O. [Effect of a surgical component to the results of radiotherapy and chemotherapy of gliomas of the brain]. Ukrayinskyy medychnyy almanakh. 2011;14(3):56-57. Ukrainian. [VernadskyNLU]
8. Chambless LB, Parker SL, Hassam-Malani L, McGirt MG, Thompson RC. Gross-total resection is associated with a survival benefit in glioblastoma multiforme. Neuro Oncol. 2011;13(3):154-63. [CrossRef]
9. Esquenazi Y, Friedman E, Liu Z, Zhu JJ, Hsu S, Tandon N. The Survival Advantage of “Supratotal” Resection of Glioblastoma Using Selective Cortical Mapping and the Subpial Technique. Neurosurgery. 2017 Aug 1;81(2):275-288. [CrossRef] [PubMed]
11. Ewelt C, Goeppert M, Rapp M, Steiger HJ, Stummer W, Sabel M. Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival. J Neurooncol. 2011 Jul;103(3):611-8. [CrossRef] [PubMed]
12. Senft C, Bink A, Franz K, Vatter H, Gasser T, Seifert V. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial. Lancet Oncol. 2011 Oct;12(11):997-1003. [CrossRef] [PubMed]
14. Ellingson BM, Harris RJ, Woodworth DC, Leu K, Zaw O, Mason WP, Sahebjam S, Abrey LE, Aftab DT, Schwab GM, Hessel C, Lai A, Nghiemphu PL, Pope WB, Wen PY, Cloughesy TF. Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials. Neuro Oncol. 2017 Jan;19(1):89-98. [CrossRef] [PubMed] [PubMed Central]
15. Socha J, Kepka L, Ghosh S, Roa W, Kumar N, Sinaika V, Matiello J, Lomidze D, de Castro DG, Hentati D, Fidarova E. Outcome of treatment of recurrent glioblastoma multiforme in elderly and/or frail patients. J Neurooncol. 2016 Feb;126(3):493-8. [CrossRef] [PubMed]
16. Patil CG, Yi A, Elramsisy A, Hu J, Mukherjee D, Irvin DK, Yu JS, Bannykh SI, Black KL, Nuсo M. Prognosis of patients with multifocal glioblastoma: a case-control study. J Neurosurg. 2012 Oct;117(4):705-11. [CrossRef] [PubMed]
18. Rozumenko V, Rozumenko A. Intraoperative fluorescence. The view at the surgery of gliomas in the light of innovative technologies. Ukrainian Neurosurgical Journal. 2016;(1):25-30. Ukrainian. [CrossRef]
19. Zozulya YuP, Glavatsky OYa, Vasylyeva IH, Chopyk NH. [Modern aspects of chemotherapy of glial brain tumors]. Zhurnal NAMN Ukrayiny. 2015;(2):158-169. Ukrainian. [VernadskyNLU]
20. Keller S, Schmidt MHH. EGFR and EGFRvIII Promote Angiogenesis and Cell Invasion in Glioblastoma: Combination Therapies for an Effective Treatment. Int J Mol Sci. 2017 Jun 18;18(6). pii: E1295. [CrossRef] [PubMed] [PubMed Central]
21. Qin JJ, Liu ZX, Wang JM, Du J, Xu L, Zeng C, Han W, Li ZD, Xie J, Li GL. Prognostic factors influencing clinical outcomes of malignant glioblastoma multiforme: clinical, immunophenotypic, and fluorescence in situ hybridization findings for 1p19q in 816 chinese cases. Asian Pac J Cancer Prev. 2015;16(3):971-7. [CrossRef] [PubMed]
22. Brandes AA, Franceschi E, Paccapelo A, Tallini G, De Biase D, Ghimenton C, Danieli D, Zunarelli E, Lanza G, Silini EM, Sturiale C, Volpin L, Servadei F, Talacchi A, Fioravanti A, Pia Foschini M, Bartolini S, Pession A, Ermani M. Role of MGMT Methylation Status at Time of Diagnosis and Recurrence for Patients with Glioblastoma: Clinical Implications. Oncologist. 2017 Apr;22(4):432-437. [CrossRef] [PubMed] [PubMed Central]
23. Calvert AE, Chalastanis A, Wu Y, Hurley LA, Kouri FM, Bi Y, Kachman M, May JL, Bartom E, Hua Y, Mishra RK, Schiltz GE, Dubrovskyi O, Mazar AP, Peter ME, Zheng H, James CD, Burant CF, Chandel NS, Davuluri RV, Horbinski C, Stegh AH. Cancer-Associated IDH1 Promotes Growth and Resistance to Targeted Therapies in the Absence of Mutation. Cell Rep. 2017 May 30;19(9):1858-1873. [CrossRef] [PubMed] [PubMed Central]
24. Dzyak LA, Zorin NA, Sirko AG, Shpohnka VI, Kozinskiy AV. [Molecular biomarkers for prognosis and optimal treatment strategy of glioblastomas]. Ukrainian Neurosurgical Journal. 2009; (4): 4-7. Russian. [Abstract/Full Text]
GOST Style Citations
Copyright (c) 2017 Andriy G. Sirko, Dmytro M. Romanukha
This work is licensed under a Creative Commons Attribution 4.0 International License.